A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as a cornerstone in the management of type 2 diabetes and obesity. The perioperative implications of GLP-1RAs in orthopaedic surgery are a growing area of interest; however, their effe…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to exert favorable effects on hepatic biomarkers and liver-related conditions, including nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. However, the optimal dosa…
BACKGROUND: In India, approximately 33-46% people are obese which is a major risk factor to several non-communicable diseases. Amongst all existing treatment modalities, semaglutide injection is the proven most effective glucagon-like peptide-1 (GLP-…
PURPOSE OF REVIEW: To examine the role of pharmacologic obesity treatment in people with type 2 diabetes (T2D), with a focus on efficacy, safety, and clinical positioning in the context of T2D-specific metabolic and therapeutic challenges. RECENT FIN…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes mellitus and weight management, with growing off-label use in young adults. While GLP-1RAs are generally well tolerated, emerging evidence suggests p…
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the management of obesity; however, respiratory complications are rarely documented. A 40-year-old person without diabetes with obesity (body mass index [BMI] 36 kg/m) developed ex…
Chronic kidney disease (CKD) incidence continues to rise along with obesity and diabetes, driving substantial medical, psychosocial, and economic burdens for patients. Beyond glycemic control and the recommended therapies of ACEI/ARB, SGLT2 inhibitor…
BACKGROUND: The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus. M…
BACKGROUND: Recent evidence has raised concerns about potential pro-oncogenic effects associated with glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, particularly regarding gastrointestinal mal…
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, random…
Glucocorticosteroids (GCs) are commonly used in the treatment of autoimmune, inflammatory and neoplastic diseases. Although clinically effective, they are associated with significant metabolic side effects, including increased insulin resistance, imp…
Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used for glycemic control in patients with type 2 diabetes and for weight loss in obese patients, have been increasingly used due to their effectiveness in treating these conditions and in r…
We present 2 case reports of the benefits of the subcutaneous once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy semaglutide in adolescents with type 1 diabetes (T1D) complicated by obesity. Two female individuals (17 and 12 years…
Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major adverse cardiovascular events (MACEs) among at-risk patients living with type 2 diabetes (T2D). Tirzepatide, a dual GIP/GLP-1 receptor agonist, dem…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading chronic liver disease on a global scale. With its increasing incidence and advances in research technologies, our understanding of the mechanisms, non-invasive diagnostic s…
BACKGROUND: Novel antiobesity medications have demonstrated significant weight loss in clinical trials. Data on real-world use of semaglutide are lacking. Such data are vital to inform health benefit design of this and other costly incretin mimetics,…
BACKGROUND: Health Canada is proposing to use decisions by foreign regulators in approving new drugs to speed up their marketing. OBJECTIVES: To investigate the length of gaps in submissions to and approvals by Health Canada compared to the Food and…
The prevalence of age-related dry eye disease (DED) is rapidly increasing with global aging, and progressive lacrimal gland (LG) dysfunction represents a central pathogenic mechanism for which targeted therapies remain limited. Semaglutide (Sema), a…